To do or not to do? Changing paradigms: value of balloon-sizing and left atrial appendage occlusion by Attinger-Toller, Adrian et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
To do or not to do? Changing paradigms: value of balloon-sizing and left
atrial appendage occlusion
Attinger-Toller, Adrian; Hager, Ph; Rickli, H; Lüscher, T F; Landmesser, U; Nietlispach, F
Abstract: Unspecified
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-107533
Published Version
Originally published at:
Attinger-Toller, Adrian; Hager, Ph; Rickli, H; Lüscher, T F; Landmesser, U; Nietlispach, F (2014).
To do or not to do? Changing paradigms: value of balloon-sizing and left atrial appendage occlusion.
Cardiovascular Medicine, 17(1):21-23.
21
CASE REPORT
Cardiovascular Medicine 2014;17(1):21–23
To do or not to do? Changing paradigms: value of 
balloon-sizing and left atrial appendage occlusion
Adrian Attinger-Toller
a
, Philipp K. Haager
b
, Hans Rickli
b
, Thomas F. Lüscher
a
, Ulf Landmesser
a
, Fabian Nietlispach
a
a
 University Heart Center, Department of Cardiology, University Hospital Zurich, Switzerland
b
 Division of Cardiology, Kantonsspital St. Gallen, Switzerland
Funding / potential 
competing interests:  
Dres. Nietlispach and 
Landmesser recieve consul-
tant fees from St. Jude 
Medical. Prof. Lüscher 
recieves research funding 
from St. Jude Medical,  
Abbott vascular and 
Medtronic.
Correspondence: 
PD Dr. med. Fabian Nietlispach 
Leitender Arzt i.V., Teamleiter TAVI 
Interventionelle Kardiologie 
Universitäres Herzzentrum 
Rämisstrasse 100 
CH-8091 Zürich 
Switzerland 
Fabian.Nietlispach[at]usz.ch
Summary
Balloon-sizing of the aortic annulus can be considered 
the “gold-standard” for annulus-assessment for tran-
scatheter aortic valve implantation (TAVI) – compara-
ble to intraoperative surgical sizing tools. We report a 
case of an 83 year-old patient referred for TAVI, 
where CT-angiogram measurements might have pre-
vented us from performing TAVI and balloon-sizing al-
lowed us to proceed with an excellent final result. Since 
patients with concomitant atrial fibrillation undergo-
ing TAVI are known to have worse short- and long-term 
outcomes, left atrial appendage occlusion (LAAO) at 
the same sitting was successfully performed, to obviate 
the need for oral anticoagulation. Combining proce-
dures (e.g. TAVI and LAAO) is technically feasible, pa- 
tient-friendly and should be encouraged where reason-
able, despite contrary financial incentives by our health 
care system.
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Case report
An 83 year old hypertensive patient with severe, symp-
tomatic aortic stenosis in NYHA III heart failure and a 
history of syncope was referred for valve replacement 
to our centre. His previous history was remarkable for 
prostate cancer, hospitalisation for decompensated 
heart failure, paroxysmal atrial fibrillation (for which 
he was on vitamin K antagonist) and a previous cere-
brovascular accident. His STS score was calculated as 
3.3% and the EuroScore II was 4.6%. The ECG showed 
atrial fibrillation at a normal heart rate (74 bpm) and 
a left bundle branch block. On 
trans thoracic echocardiography a 
mean gradient of 39 mm Hg was 
found and the indexed aortic valve 
area was 0.5 cm/m
2
. The left ventri-
cle was mildly dilated with a left 
ventricular ejection fraction of 
35%. Significant coronary artery 
disease could be excluded by coro-
nary angiography. 
Due to his age and his metastasising prostate can-
cer, the patient refused to undergo open-heart surgery. 
Technical eligibility for transcatheter valve implanta-
tion was therefore evaluated. The angiography showed 
that the peripheral arteries were large enough for a 
transfemoral procedure, in that they could accommo-
date an 18French sheath. Annulus sizing was per-
formed by CT-angiography revealing sinuses of Vals-
alva of 41 mm, a mean annulus diameter of 31.5 mm 
(min. 26 mm, max. 37 mm), a perimeter of 102 mm and 
an annulus area of 720 mm
2
. The largest device cur-
rently available is the 31 mm CoreValve prosthesis 
with a device area of 755 mm
2
 and a perimeter of 97 
mm. For the use of this valve type, a maximum annular 
area of 660 mm
2
 and a maximum perimeter of 91 mm 
to achieve reasonable 7–14% over-sizing is recom-
mended. Despite the above-mentioned measurements 
on CT, it was decided to proceed with balloon-sizing of 
the annulus based on the angiographic impression 
(suggesting feasibility of TAVI) and if this showed good 
sealing to proceed ad-hoc with the valve implantation.
The procedure was performed with local anaesthe-
sia and with fluoroscopic guidance only. An 18French 
Cook sheath (Cook Medical Inc., Bloomington, USA) 
was introduced via the right femoral artery after pre-
closure with two Perclose ProGlides (Abbott Vascular, 
Abbott Park, USA). Balloon-sizing was performed us-
ing a 26-mm Z-Med Balloon (NuMED Inc., Hopkinton, 
USA). Aortic balloon sizing was performed under rapid-
pacing using simultaneous contrast injection to the 
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aortic root. Minimal aortic regurgitation was seen dur-
ing valvuloplasty and the decision was taken to pursue 
with implantation of a CoreValve 31-mm prosthesis 
(Medtronic, Minneapolis, USA). After valve implanta-
tion, a large pulse-pressure and a high left ventricular 
end-diastolic pressure were evident. Reusing the 26-
mm Z-Med balloon, a postdilatation was performed 
which improved haemodynamics (LVEDP 13 mm Hg, 
diastolic blood pressure 43 mm Hg, systolic blood pres-
sure 106 mm). The final aortogram showed mild aortic 
regurgitation.
Valve implantation was followed by transseptal 
puncture through a right femoral venous access using 
an 8French Mullins transseptal sheath and the Brock-
enbrough Curved Needle (Medtronic, Minneapolis, 
USA). Using contrast injections through the transsep-
tal sheath, the left atrial appendage (LAA) was visual-
ised and a thrombus within the left atrial appendage 
was not detected. The transseptal sheath was replaced 
by the Amplatzer TorqueVue 45×45 sheath (St. Jude 
Medical, St. Paul, USA). Sizing of the left atrial ap-
pendage was performed using the outer diameter of the 
delivery sheath as a reference (14F; 5.4 mm; fig. 1). An 
Amplatzer Amulet 28 mm LAA-Occluder (St. Jude 
Medical, St. Paul, USA) was deployed in the left atrial 
appendage in a stable position with good sealing 
(fig. 2).
The following day, a transthoracic echocardiogra-
phy confirmed a well-functioning CoreValve prosthesis 
with only trivial paravalvular regurgitation and a 
mean transvalvular gradient of 5 mm Hg as well as the 
correct position of the Amplatzer Amulet 28-mm Oc-
cluder. 
Discussion
In most centres, CT-scans are routinely performed 
prior to transcatheter aortic valve implantation (TAVI) 
for annulus sizing and to depict the annular coronary 
distance [1]. Standard protocols facilitate patient man-
agement and standardised investigations also help to 
feed registry databases for future scientific analyses. 
Furthermore, multimodality imaging and heart-team 
approaches allow sharing of responsibilities, also in 
case a complication occurs. Routine work-up consists of 
transthoracic, followed by transoesophageal echocardio-
graphy, a coronary angiogram, aortogram and angio-
gram of the peripheral vessels, followed by a CT-angio-
gram. Balloon-sizing of the aortic annulus is only per-
formed in borderline cases. In our patient, CT-angiogram 
measurements might have prevented us from perform-
ing TAVI and balloon-sizing allowed us to proceed with 
TAVI with an excellent result.
Therefore, the question arises, why not bypass 
Figure 2
Combined interventions: Combined transcatheter aortic valve 
replacement and left atrial appendage occlusion. (*) Amplatzer Amulet 
28 mm; (**) Amplatzer TorqueVue Sheath 14F; (#) CoreValve 31 mm.
Figure 1
Fluoroscopic sizing of the left atrial appendage (LAA) landing zone: the 
outer diameter of the 14F sheath measures 5.4 mm (single white 
arrow). The device landing zone measured approx. 23 mm (almost 4.5x 
the outer diameter of the sheath; serial white arrows). Therefore, a 28 
mm device was chosen.
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some previous investigations and proceed to balloon-
sizing right away? Currently, there are no data pub-
lished comparing CT-sizing with balloon-sizing, how-
ever, if in borderline cases we rely most on balloon-siz-
ing, the technique may be considered as a 
“gold-standard”. Balloon-sizing not only gives excellent 
anatomical and functional information about the annu-
lar size, but also allows the assessment of the position 
of the native valve leaflets in relation to the left main 
and right coronary arteries and to determine their pa-
tency. With the concept of balloon-sizing, ad-hoc TAVI 
becomes a reality in selected patients. A sophisticated 
pressure-based technique of balloon-sizing was pro-
posed by Babaliaros and colleagues [2], but a simplified 
version relying on fluoroscopic assessment of contrast 
injections is equally reliable in our experience (assess-
ment of aortic regurgitation and coronary flow with a 
fully inflated balloon).
As already demonstrated, a combined approach 
with catheter-based aortic valve implantation and oc-
clusion of the left atrial appendage is technically feasi-
ble [3–5], as is ad-hoc left atrial appendage occlusion 
without previous and intraprocedural transoesopha-
geal echocardiography [6]. Combined procedures allow 
for a patient-friendly treatment, despite contrary fi-
nancial incentives by our health care system. Since el-
derly and multimorbid patients are at increased risk 
for intracranial and gastrointestinal bleeding as recog-
nised by elevated HAS-BLED Scores (in our patient 
the HAS-BLED Score summed up to 3), combined in-
terventions are not only patient-friendly, but may also 
be safer. Left atrial appendage closure represents an 
alternative to oral anticoagulants for patients with 
atrial fibrillation and is probably one of the most un-
der-performed procedures in cardiology. Long-term 
data from the PROTECT AF trial have now shown not 
only superiority in terms of stroke prevention, but also 
a sig nificant 60% reduction in cardiovascular mortality 
and a 34% reduction in all-cause mortality as com-
pared to oral anticoagulation (4-year F/U PROTECT 
AF trial; D. Holmes, presented at EuroPCR 2013). 
Given these data together with the latest long-term re-
sults on left atrial appendage closure with Amplatzer 
occluders [7], left atrial appendage closure should be 
considered an attractive alternative to systemic oral 
anticoagulation in suitable patients with atrial fibrilla-
tion. 
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